BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20930946)

  • 1. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
    Shi L; Wang S; Zangari M; Xu H; Cao TM; Xu C; Wu Y; Xiao F; Liu Y; Yang Y; Salama M; Li G; Tricot G; Zhan F
    Oncotarget; 2010 May; 1(1):22-33. PubMed ID: 20930946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
    Zhan F; Colla S; Wu X; Chen B; Stewart JP; Kuehl WM; Barlogie B; Shaughnessy JD
    Blood; 2007 Jun; 109(11):4995-5001. PubMed ID: 17303695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
    Bhutani M; Pathak AK; Nair AS; Kunnumakkara AB; Guha S; Sethi G; Aggarwal BB
    Clin Cancer Res; 2007 May; 13(10):3024-32. PubMed ID: 17505005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes?
    Huang CW; Lin CY; Huang HY; Liu HW; Chen YJ; Shih DF; Chen HY; Juan CC; Ker CG; Huang CY; Li CF; Shiue YL
    Ann Surg Oncol; 2010 Mar; 17(3):907-22. PubMed ID: 19866239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.
    Zeng Z; Gao ZL; Zhang ZP; Jiang HB; Yang CQ; Yang J; Xia XB
    Int J Mol Med; 2019 Jul; 44(1):103-114. PubMed ID: 31115482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
    Shaughnessy J
    Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
    Pandey MK; Sung B; Aggarwal BB
    Int J Cancer; 2010 Jul; 127(2):282-92. PubMed ID: 19937797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
    Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
    Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
    Kannappan R; Yadav VR; Aggarwal BB
    J Biol Chem; 2010 Oct; 285(43):33520-33529. PubMed ID: 20720018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
    Fan JL; Zhang J; Dong LW; Fu WJ; Du J; Shi HG; Jiang H; Ye F; Xi H; Zhang CY; Hou J; Wang HY
    Cell Death Dis; 2014 Mar; 5(3):e1126. PubMed ID: 24625985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
    Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
    PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
    Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
    Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways.
    Wang H; Sun M; Guo J; Ma L; Jiang H; Gu L; Wen H; Liao S; Chen J; Zeng B; Li Y; Li Y; Yu X; Feng Y; Zhou Y
    Biochem Pharmacol; 2017 Jul; 135():35-49. PubMed ID: 28288818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
    Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
    Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells.
    Park S; Lee HJ; Jeong SJ; Song HS; Kim M; Lee HJ; Lee EO; Kim DH; Ahn KS; Kim SH
    Food Chem Toxicol; 2011 Jun; 49(6):1367-72. PubMed ID: 21420464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.